Nanosized Bilosomes as a Potential Platform for Improved Therapeutic Efficacy of Capecitabine Against Colon Cancer in Rats: Formulation, Evaluation, and Optimization
The preprint develops and optimizes capecitabine-loaded nanosized bilosomes using response surface methodology, identifying a formulation with approximately 243 nm vesicles, 89.5% drug entrapment, a high negative zeta potential, and sustained drug release. Compared with free capecitabine, the optimized bilosomes improved ex vivo intestinal permeation by about 2.4-fold and increased rat exposure, including a 5.96-fold rise in relative bioavailability and longer mean residence time. In dimethylhydrazine-induced colorectal cancer rats, treatment reduced serum CEA and CA 19-9, lowered MMP-9 and VEGF-A expression, and produced better colon histology than free capecitabine. The findings support bilosomes as a potential oral delivery platform, although the work is a non-peer-reviewed preprint and the results are limited to preclinical animal models.
Haber tarzıBilgilendirici
Predominantly evidence-based experimental research, though the conclusions use favorable and promotional language about the optimized formulation.




